{"id":920918,"date":"2025-12-18T09:32:12","date_gmt":"2025-12-18T14:32:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/"},"modified":"2025-12-18T09:32:12","modified_gmt":"2025-12-18T14:32:12","slug":"natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/","title":{"rendered":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer<\/b><\/p>\n<p class=\"bwalignc\"><i>JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a &gt;40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54379763&amp;newsitemid=20251218169743&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=f3ad3df5659130f2f4dbbbc5d2e14c17\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)\/SWOG 80702 study in <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamaoncology%2Farticle-abstract%2F2842596&amp;esheet=54379763&amp;newsitemid=20251218169743&amp;lan=en-US&amp;anchor=JAMA+Oncology&amp;index=2&amp;md5=0960610338f62c05d26cea86e6b6ed90\"><i>JAMA Oncology<\/i><\/a>. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology\u2019s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year.\n<\/p>\n<p>\nCALGB (Alliance)\/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with stage III colorectal cancer (CRC). The pre-specified post-hoc analysis included 940 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX +\/- celecoxib, a non-steroidal anti-inflammatory drug (NSAID). Key findings included:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Adding celecoxib to conventional chemotherapy in Signatera-positive patients, after surgery reduced the risk of cancer recurrence and death by ~40%. <\/b>Celecoxib improved disease-free survival (DFS) (adjusted HR=0.61, 95% CI 0.42-0.89; 3-year 41.0% vs. 22.6%) and overall survival (OS) (adjusted HR=0.62, 95% CI 0.40-0.96; 5-year: 61.6% vs. 39.9%) compared to placebo in Signatera-positive patients.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Celecoxib benefit in Signatera-positive patients was independent of demographic, pathologic or molecular factors, including <i>PIK3CA<\/i> status, further defining a patient population who may benefit from the addition to adjuvant treatment. <\/b>Celecoxib improved DFS of Signatera-positive patients for both <i>PIK3CA <\/i>wild-type (adjusted HR=0.64, 95% CI 0.42-0.98) and <i>PIK3CA <\/i>altered (adjusted HR=0.19, 95% CI 0.06-0.58) tumors. No benefit was observed in Signatera-negative patients (<i>PIK3CA <\/i>wild-type adjusted HR=0.80, 95% CI 0.55-1.18; <i>PIK3CA<\/i> altered HR=0.85, 95% CI 0.33-2.24).\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>New analysis showed statistical significance in the interaction between MRD status and treatment randomization. <\/b>In 66% of patients with plasma and DNA samples that would pass minimum QC criteria for Signatera analysis in the CLIA lab, analysis showed an even stronger benefit for adjuvant celecoxib than in the overall cohort (adjusted HR=0.49); and it showed significance in the statistical interaction test comparing the effect of celecoxib vs. placebo between patients who were Signatera positive vs. negative. In Natera\u2019s standard lab practice, 99% of plasma and DNA samples meet QC criteria.\n<\/li>\n<\/ul>\n<p>\n\u201cFor patients with detectable ctDNA after surgery, adding celecoxib to standard chemotherapy improved both DFS and OS,\u201d said Jonathan Nowak, M.D., Ph.D., Brigham and Women\u2019s Hospital, and corresponding author of the publication. \u201cIn addition to highlighting Signatera\u2019s predictive abilities in this setting, the publication also underscores its value as a prognostic marker for disease recurrence and survival.\u201d\n<\/p>\n<p>\n\u201cThis publication marks another important milestone in colorectal cancer research, highlighting Signatera as a critical tool in disease management,\u201d said Adham Jurdi, M.D., senior medical director of GI oncology at Natera. \u201cIt further demonstrates Signatera\u2019s predictive utility in identifying, with great precision, patients with MRD who will likely benefit from celecoxib in addition to chemotherapy, regardless of their <i>PIK3CA <\/i>status.\u201d\n<\/p>\n<p><b>About Natera<\/b><\/p>\n<p>\nNatera\u2122 is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54379763&amp;newsitemid=20251218169743&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=3&amp;md5=f1fd186f8bc98b070a026ed760562ec6\">www.natera.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in \u201cRisk Factors\u201d in Natera\u2019s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54379763&amp;newsitemid=20251218169743&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=4&amp;md5=d59a2c6c3ece473b2688ce37273d089d\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54379763&amp;newsitemid=20251218169743&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=507fec7196ef2ef67f96296509b8e9bd\">www.sec.gov<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251218169743\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251218169743\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<br \/>\n<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Clinical Trials Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251218169743\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a &gt;40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)\/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology\u2019s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)\/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-920918","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a &gt;40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)\/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology\u2019s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)\/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with &hellip; Continue reading &quot;Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:32:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\\\/SWOG 80702 Study in Colorectal Cancer\",\"datePublished\":\"2025-12-18T14:32:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/\"},\"wordCount\":850,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/\",\"name\":\"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\\\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-12-18T14:32:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\\\/SWOG 80702 Study in Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk","og_description":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a &gt;40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)\/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology\u2019s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)\/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with &hellip; Continue reading \"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-18T14:32:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer","datePublished":"2025-12-18T14:32:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/"},"wordCount":850,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/","name":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-12-18T14:32:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251218169743r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-announces-publication-of-signatera-analysis-from-randomized-phase-iii-calgb-alliance-swog-80702-study-in-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera Announces Publication of Signatera\u2122 Analysis from Randomized, Phase III CALGB (Alliance)\/SWOG 80702 Study in Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=920918"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920918\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=920918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=920918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=920918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}